Position in CELC
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$385,222,500
+$74,920,289 QoQ
Shares Held
3,375,000
+8.5% QoQ
Ownership
6.92%
of shares outstanding
% of Portfolio
3.79%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Derivatives in CELC
reported options exposure · as of Mar 31, 2026CallValue
$22,828,000
CallShares
200,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Avoro Capital Advisors LLC holds $8,549,473,651 across 28 Biotechnology names. CELC ranks #9 (4.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
5,062,500 | $1,157,945,625 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
1,818,181 | $951,763,208 | |
| 3 | KRYS |
Krystal Biotech, Inc.
|
2,888,888 | $746,257,548 | |
| 4 | ARGX |
Argenx SE
|
1,000,000 | $730,250,000 | |
| 5 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
10,699,999 | $670,889,937 | |
| 6 | KYMR |
Kymera Therapeutics, Inc.
|
7,474,747 | $622,571,677 | |
| 7 | APLS |
Apellis Pharmaceuticals, Inc.
|
12,222,222 | $491,699,991 | |
| 8 | CNTA |
Centessa Pharmaceuticals plc
|
11,430,455 | $454,017,672 |
All Filings in CELC
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $22,828,000 | 200,000 | Call | Sole | 2026-05-15 | |
| 2026-03-31 | $385,222,500 | 3,375,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $310,302,211 | 3,111,111 | Shares | Sole | 2026-03-16 | |
| No filing history on record for this holder in this stock. | ||||||